With advances in technology and many innovative treatments on the horizon, cell and gene therapies can reshape healthcare, giving hope to patients who previously had no therapeutic options. But when will their potential be fully realised?

Under the stewardship of The Economist’s editorial team, this event will convene industry leaders and healthcare stakeholders to debate the challenges of introducing advanced therapies into the mainstream. It will discuss changes in regulatory landscapes, delivery models, structuring clinical trials and gathering real-world evidence that can improve patient access while ensuring companies maintain a competitive edge.

Join industry leaders and healthcare stakeholders in discussing barriers to advancing these innovative therapies and how to improve patient access.

Speakers include